Science 37 Launches Dedicated Pediatrics Department to Expand Access to Specialized Clinical Research for Children and Families
Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation
Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
eMed completes tender offer for all outstanding shares of Science 37
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
eMed commences tender offer for Science 37
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
Shareholder Alert: Ademi LLP investigates whether Science 37 Holdings, Inc. has obtained a Fair Price in its transaction with eMed
SNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Science 37 Holdings, Inc. Is Fair to Shareholders
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
Science 37 Receives Top Honors in Everest PEAK Matrix®
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023
Science 37 Holdings, Inc. (SNCE) Q3 2023 Earnings Call Transcript
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Science 37 Reports Third Quarter 2023 Financial Results
Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
Science 37 Holdings, Inc. (SNCE) Q2 2023 Earnings Call Transcript
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Best Penny Stocks To Buy This Week? 3 Under $0.99 To Watch
Science 37 Reports Second Quarter 2023 Financial Results
Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Science 37 to Report First Quarter 2023 Financial Results on May 15, 2023
Why Is Science 37 (SNCE) Stock Up 9% Today?
Science 37 to Present at the Cowen 43rd Annual Health Care Conference
Science 37 to Report Fourth Quarter 2022 Financial Results on March 6, 2023
Science 37 to Present at the 5ᵗʰ Annual Evercore ISI HealthCONx Conference
Science 37 Holdings, Inc. (SNCE) Q3 2022 Earnings Call Transcript
Science 37 Holdings, Inc. (SNCE) Reports Q3 Loss, Misses Revenue Estimates
Science 37 to Report Third Quarter 2022 Financial Results on November 10, 2022
Science 37 to Present at the Baird 2022 Global Healthcare Conference
Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q2 2022 Results - Earnings Call Transcript
Science 37 to Report Second Quarter 2022 Financial Results on August 11, 2022
Science 37® to Participate in Upcoming Investor Conferences